NRX Pharmaceuticals Inc (NRXP)

[TurdBlossom]

Geneva, Switzerland, and Newton, MA, USA, January 25, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, and Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001. ACER-001 (sodium phenylbutyrate) powder is a taste-masked, immediate release proprietary formulation in development for the treatment of urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD).

Is Relief looking to use ACER to list on the Nasdaq? Does this decrease the likelihood of a NeuroRx / Relief future merger? The two companies going their own ways but joined by Aviptadil profit sharing? Not sure what the endgame is here. Thoughts?